Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
COSCIENS Biopharma Inc. (CSCI.TO)
Toronto, ON, CA
COSCIENS Biopharma Inc., a life science company, develops and commercializes products for the cosmeceutical, nutraceutical and pharmaceutical markets in the United States, Germany, the United Kingdom, and internationally. It operates through Active Ingredient and Pharmaceutical segments. The company offers active ingredients comprising oat beta glucan, a functional ingredient that supports overall health and wellness; oat powder and peptides; oat oil which is extracted from whole oat kernels by a gentle process that retains all the important biologically active components; and avenanthramides, a natural-based ingredients used to inflammation-based diseases for the cosmeceutical and pharmaceutical industries. It also provides Macrilen/Ghryvelin (macimorelin), an orally active peptidomimetic small molecule that stimulates the secretion of growth hormone from the pituitary gland. The company sells its products through its distribution network. It has license agreements with Pharmanovia, Davimed GmbH, and NK MEDITECH Ltd, as well as Agriculture Canada, Canadian Government, and University of Alberta. The company was formerly known as Aeterna Zentaris Inc. and changed its name to COSCIENS Biopharma Inc. in August 2024. COSCIENS Biopharma Inc. was incorporated in 1990 and is based in Toronto, Canada.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +1.93% | +1.93% | -1.86% | -3.65% | -17.50% | -7.04% | -48.24% | -83.94% | -97.41% | -99.39% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-08 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Medical - Pharmaceuticals: +7.8%+69.6% ★ Q1'26: +64,644.6% (vs Q1'24)
-
EPS growth Medical - Pharmaceuticals: +20.2%-73.4% Q1'26: +63.5% (vs Q1'24)
-
FCF margin FCF growth · Medical - Pharmaceuticals: +43.3%-131.3% Q1'26: -115.4% (vs Q1'24)
-
EBIT margin Medical - Pharmaceuticals: +6.8%-139.3% Q1'26: -38.7% (vs Q1'24)
-
ROIC Medical - Pharmaceuticals: +6.1%— Q1'26: -23.3% (vs Q1'24)
-
Share dilution Medical - Pharmaceuticals: +0.0%-34.8% ★ Q1'26: +3.5% (vs Q1'24)
-
Debt / EBITDA Net debt/EBITDA · Medical - Pharmaceuticals: 0.21×-0.23× Q1'26: -1.32× (vs Q1'24)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Dec 2024 actual |
|---|---|
| Revenue |
4.30M
est.
|
| EBITDA |
-2.97M
est.
|
| EBIT |
-3.00M
est.
|
| Net Income |
-65.46M
est.
|
| SGA |
18.15M
est.
|
| EPS |
-13.48
est.
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Klaus Paulini | President & CEO | 518.6K | — |
| Giuliano La Fratta | Senior Vice President of Finance & Chief Financial Officer | 399.1K | male |
| Leslie Auld | Senior VP & CFO | 365.0K | female |
| Matthias Gerlach | Senior VP & Managing Director of COSCIENS | 329.7K | — |
| Michel Regnier | Senior VP & MD of Edmonton | 281.6K | male |
| Nicola Ammer | Senior VP & Chief Medical Officer | 269.8K | — |
| Michael Teifel | Senior Vice President of Non-Clinical Development & Chief Scientific Officer | 259.1K | — |
| Peter Harry Puccetti | Interim CEO & Independent Chairman | 101.4K | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for CSCI.TO
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
